Details for New Drug Application (NDA): 212722
✉ Email this page to a colleague
NDA 212722 describes PIRFENIDONE, which is a drug marketed by Accord Hlthcare, Amneal, Apotex, Chartwell Rx, Laurus, Sandoz, Sciegen Pharms Inc, Aizant, Alembic, Hetero Labs Ltd V, Micro Labs, MSN, and Teva Pharms Usa, and is included in twenty NDAs. It is available from twenty suppliers. Additional details are available on the PIRFENIDONE profile page.
The generic ingredient in PIRFENIDONE is pirfenidone. There are twenty-three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the pirfenidone profile page.
The generic ingredient in PIRFENIDONE is pirfenidone. There are twenty-three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the pirfenidone profile page.
Summary for 212722
| Tradename: | PIRFENIDONE |
| Applicant: | Laurus |
| Ingredient: | pirfenidone |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212722
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PIRFENIDONE | pirfenidone | TABLET;ORAL | 212722 | ANDA | Laurus Labs Limited | 42385-924 | 42385-924-99 | 3 BOTTLE in 1 CARTON (42385-924-99) / 90 TABLET, FILM COATED in 1 BOTTLE |
| PIRFENIDONE | pirfenidone | TABLET;ORAL | 212722 | ANDA | Laurus Labs Limited | 42385-925 | 42385-925-90 | 90 TABLET, FILM COATED in 1 BOTTLE (42385-925-90) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 267MG | ||||
| Approval Date: | Jul 19, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 534MG | ||||
| Approval Date: | Jul 19, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 801MG | ||||
| Approval Date: | Jul 19, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
